Early molecular causes of pathological cardiac hypertrophy and failure

病理性心脏肥大和衰竭的早期分子原因

• 批准号: nhmrc : 1052659
• 负责人: Dr Francine Marques
• 金额: $ 20.79万
• 依托单位: Baker IDI Heart and Diabetes Institute
• 依托单位国家: 澳大利亚
• 项目类别: Early Career Fellowships
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/early-molecular-causes-hypertrophy-failure/112290
• 关键词: Early; molecular; causes; pathological; cardiac

Pathological increase in heart size is a common condition in Australia. Small regulatory RNAs are now known to have a role in the normal development of the heart. Therefore we want to identify and then test the use of small RNA molecules as prevention and therapy for heart enlargement in an animal model. We will also identify different combinations of changes in the DNA sequence that could be used as markers for the predisposition of increased heart.

心脏大小的病理性增加在澳大利亚是一种常见的疾病。现在已知小的调节RNA在心脏的正常发育中起作用。因此，我们希望在动物模型中鉴定并测试小RNA分子作为心脏扩大的预防和治疗的用途。我们还将确定DNA序列变化的不同组合，这些变化可用作心脏增加倾向的标志物。